How Innovation and Creativity Drive American Innovation
January 19, 2021 2:30 PM to 3:30 PM
Join special guest speakers,Senator Thom Tillis and USPTO Director Andrei Iancu, for an in-depth discussion about the important role innovation and creativity play in ensuring American competitiveness, economic growth, and groundbreaking discoveries.
Every innovation and creation starts with a novel or original idea...and that’s why innovations and creative works must be respected and honored. America’s strong intellectual property system is essential to achieving that goal. They allow ideas—from a back-of-the-napkin concept to the most complex designs—to be nurtured and developed into full-fledged inventions that benefit humanity.
Senator Tillis and Director Iancu are recognized as experts and thought leaders on the policies and resources needed to support our innovation and creative economy. Through their leadership in their respective roles, they bring unique perspectives and insights on how America can remain at the forefront of the global economy and the leader in innovation in the 21st century. The event, hosted by the US Chamber Global Innovation Policy Center, the International Trademark Association, and the Intellectual Property Owners Association, is open to the public.
News
-
AIPLA Submits Comments on the World Intellectual Property Organization Riyadh Design Law Treaty
June 24, 2026
Alexandria, VA. June 11, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments on the World Intellectual Property Organization Riyadh Design Law Treaty. -
.png?sfvrsn=143e8f56_1 "supreme court")
AIPLA Files Amicus Brief in Arbutus Biopharma Corp. v. Moderna, Inc.
June 22, 2026
Arlington, VA. June 5, 2026 – The American Intellectual Property Law Association (AIPLA) filed an amicus brief in Arbutus Biopharma Corp. v. Modernatx, Inc. -
Supreme Court Issues Unanimous Decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc.
June 4, 2026
On June 4, 2026, the Supreme Court issued a unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. While the Court reaffirmed existing law on pleading standards, it reversed the Federal Circuit’s decision that had focused on how relevant statements could be understood by medical providers as instructions to infringe. The amicus brief filed by AIPLA on March 27, 2026, advocated for affirmance and cautioned the Court not to change the patent infringement pleading standard or adopt any categorical exemption from inducement for a particular industry. -
AIPLA Views on H.R. 3269, the “ETHIC Act,” and H.R. 6485, the “Skinny Labels, Big Savings Act”
June 3, 2026
Arlington, VA. June 3, 2026 – The American Intellectual Property Law Association (AIPLA) submitted a letter to the House Judiciary Committee’s Subcommittee on Courts, Intellectual Property, Artificial Intelligence, and the Internet outlining its views on H.R. 3269, the “ETHIC Act,” and H.R. 6485, the “Skinny Labels, Big Savings Act.” -
AIPLA Submits Comments to the USPTO on 2026 Supplemental GUI Guidance
May 15, 2026
Arlington, VA. May 12, 2026 – The American Intellectual Property Law Association (AIPLA) submitted comments to the USPTO on its Supplemental Guidance for Examination of Design Patent Applications Related to Computer-Generated Interfaces and Icons, issued on March 13, 2026.